AU2016361834B2 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer Download PDF

Info

Publication number
AU2016361834B2
AU2016361834B2 AU2016361834A AU2016361834A AU2016361834B2 AU 2016361834 B2 AU2016361834 B2 AU 2016361834B2 AU 2016361834 A AU2016361834 A AU 2016361834A AU 2016361834 A AU2016361834 A AU 2016361834A AU 2016361834 B2 AU2016361834 B2 AU 2016361834B2
Authority
AU
Australia
Prior art keywords
amino
pyridazin
acetamide
thiadiazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016361834A
Other languages
English (en)
Other versions
AU2016361834A1 (en
Inventor
Andrew Bailey
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
David Robert Perkins
Piotr Antoni Raubo
Peter Duncan Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of AU2016361834A1 publication Critical patent/AU2016361834A1/en
Application granted granted Critical
Publication of AU2016361834B2 publication Critical patent/AU2016361834B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AU2016361834A 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer Active AU2016361834B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
US62/260,784 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
AU2016361834A1 AU2016361834A1 (en) 2018-07-12
AU2016361834B2 true AU2016361834B2 (en) 2019-11-14

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016361834A Active AU2016361834B2 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (28)

Country Link
US (1) US10040789B2 (enExample)
EP (1) EP3383872B1 (enExample)
JP (1) JP6821680B2 (enExample)
KR (1) KR20180083411A (enExample)
CN (1) CN108349965B (enExample)
AR (1) AR106875A1 (enExample)
AU (1) AU2016361834B2 (enExample)
BR (1) BR112018008330B1 (enExample)
CA (1) CA3005517C (enExample)
CL (1) CL2018001409A1 (enExample)
CO (1) CO2018006930A2 (enExample)
DK (1) DK3383872T3 (enExample)
DO (1) DOP2018000135A (enExample)
EA (1) EA035519B9 (enExample)
ES (1) ES2796562T3 (enExample)
IL (1) IL259508A (enExample)
MX (1) MX2018006483A (enExample)
MY (1) MY195680A (enExample)
NI (1) NI201800063A (enExample)
NZ (1) NZ743699A (enExample)
PE (1) PE20181522A1 (enExample)
PH (1) PH12018501133A1 (enExample)
SG (1) SG11201803808VA (enExample)
SV (1) SV2018005700A (enExample)
TN (1) TN2018000118A1 (enExample)
TW (1) TW201731511A (enExample)
WO (1) WO2017093301A1 (enExample)
ZA (1) ZA201804361B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途
WO2025196447A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors
WO2025196446A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US20140142081A1 (en) * 2012-11-22 2014-05-22 Agios Pharmaceuticals, Inc Compounds and their methods of use
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US20140142081A1 (en) * 2012-11-22 2014-05-22 Agios Pharmaceuticals, Inc Compounds and their methods of use
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AJIT G. THOMAS ET AL, "Small molecule glutaminase inhibitors block glutamate release from stimulated microglia", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, vol. 443(1), pages 32 - 36 *

Also Published As

Publication number Publication date
US20170333429A1 (en) 2017-11-23
PH12018501133A1 (en) 2019-01-21
MX2018006483A (es) 2019-08-12
CA3005517C (en) 2023-12-12
US10040789B2 (en) 2018-08-07
CA3005517A1 (en) 2017-06-08
PE20181522A1 (es) 2018-09-24
DOP2018000135A (es) 2018-06-30
JP2018535235A (ja) 2018-11-29
MY195680A (en) 2023-02-03
EA035519B9 (ru) 2020-08-10
CL2018001409A1 (es) 2018-12-07
ES2796562T3 (es) 2020-11-27
CO2018006930A2 (es) 2018-10-10
AR106875A1 (es) 2018-02-28
TN2018000118A1 (en) 2019-10-04
SV2018005700A (es) 2019-03-07
IL259508A (en) 2018-07-31
TW201731511A (zh) 2017-09-16
CN108349965A (zh) 2018-07-31
SG11201803808VA (en) 2018-06-28
EP3383872B1 (en) 2020-05-20
BR112018008330A2 (pt) 2018-10-30
EA035519B1 (ru) 2020-06-29
EP3383872A1 (en) 2018-10-10
ZA201804361B (en) 2019-07-31
AU2016361834A1 (en) 2018-07-12
DK3383872T3 (da) 2020-06-08
WO2017093301A1 (en) 2017-06-08
JP6821680B2 (ja) 2021-01-27
NZ743699A (en) 2023-02-24
EA201891239A1 (ru) 2018-11-30
NI201800063A (es) 2018-10-18
KR20180083411A (ko) 2018-07-20
BR112018008330B1 (pt) 2023-03-07
CN108349965B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
US10294221B2 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
AU2016363718B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
AU2016363719B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
HK1260707B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)